PRKD1 and glucose measurement: In HFD-fed mice, viperin ASO increased phosphorylation of ACC and PKCμ (Figure 6F, 6G), representing a therapeutic target for mitigating lipid accumulation, glucose intolerance and maladaptive remodeling [32–34].